Related Content
- NewslettersApril 3, 2026 – April 16, 2026
OCC and FDIC Issue Final Rule Prohibiting Use of Reputation Risk in Supervisory Frameworks
- NewslettersMarch 29, 2026 – April 9, 2026
SEC Announces Enforcement Results for 2025
- NewslettersMarch 19, 2026 – April 2, 2026
OCC Rescinds Recovery Planning Standards and Guidelines
- NewslettersMarch 13, 2026 – March 27, 2026
SEC’s Compliance and Disclosure Interpretations Now Known as Corporation Finance Interpretations (CFIs)
- NewslettersMarch 5, 2026 – March 19, 2026
Kansas City Fed Approves Limited Purpose Account for Kraken Financial
- NewslettersMarch 1, 2026 – March 12, 2026
SEC Adopts Rules to Implement Section 16 Filing Requirements for Insiders of FPIs; Separately Adopts Conditional Exemptions to Requirements for Insiders of FPIs Incorporated in Select Countries
- NewslettersFebruary 19, 2026 – March 4, 2026
New York Proposes New Regulations for Buy-Now-Pay-Later Loans
- NewslettersFebruary 13, 2026 – February 27, 2026
SEC Chairman Atkins Speaks on Steps SEC is Taking to Encourage IPOs
- Press ReleaseApril 15, 2026
Goodwin Advises Obsidian Therapeutics on Merger With Galera Therapeutics and $350 Million Private Placement Financing
- In the PressApril 14, 2026
Weight-Loss Drug M&A Engorges Deal Values in 2025, Driven by Fat Cheque for Metsera – Dealspeak EMEA (Mergermarket)
- Press Release13 April 2026
Goodwin Advises Tinicum and Blackstone on Their Recommended £1.275 Billion Offer for Senior Plc
- In the PressApril 7, 2026
March's Billion-Dollar Healthcare Deals Signal More to Come (Law360)
- Awards and RankingsApril 6, 2026
Six Goodwin Lawyers and Professionals Selected for Law360 Editorial Advisory Boards
- Press ReleaseApril 6, 2026
Goodwin Advises Centerview and Guggenheim on $2.9 Billion Sale of Soleno Therapeutics to Neurocrine Biosciences
- Awards and RankingsApril 3, 2026
Goodwin is Number One for M&A in Q1 2026
- Press ReleaseApril 2, 2026
Goodwin Advises Document Crunch in Acquisition by Trimble